FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2917253389> ?p ?o ?g. }

• W2917253389 endingPage "773" @default.
• W2917253389 startingPage "773" @default.
• W2917253389 abstract "Use of thiopurines may be limited by myelosuppression. TPMT pharmacogenetic testing identifies only 25% of at-risk patients of European ancestry. Among patients of East Asian ancestry, NUDT15 variants are associated with thiopurine-induced myelosuppression (TIM).To identify genetic variants associated with TIM among patients of European ancestry with inflammatory bowel disease (IBD).Case-control study of 491 patients affected by TIM and 679 thiopurine-tolerant unaffected patients who were recruited from 89 international sites between March 2012 and November 2015. Genome-wide association studies (GWAS) and exome-wide association studies (EWAS) were conducted in patients of European ancestry. The replication cohort comprised 73 patients affected by TIM and 840 thiopurine-tolerant unaffected patients.Genetic variants associated with TIM.Thiopurine-induced myelosuppression, defined as a decline in absolute white blood cell count to 2.5 × 109/L or less or a decline in absolute neutrophil cell count to 1.0 × 109/L or less leading to a dose reduction or drug withdrawal.Among 1077 patients (398 affected and 679 unaffected; median age at IBD diagnosis, 31.0 years [interquartile range, 21.2 to 44.1 years]; 540 [50%] women; 602 [56%] diagnosed as having Crohn disease), 919 (311 affected and 608 unaffected) were included in the GWAS analysis and 961 (328 affected and 633 unaffected) in the EWAS analysis. The GWAS analysis confirmed association of TPMT (chromosome 6, rs11969064) with TIM (30.5% [95/311] affected vs 16.4% [100/608] unaffected patients; odds ratio [OR], 2.3 [95% CI, 1.7 to 3.1], P = 5.2 × 10-9). The EWAS analysis demonstrated an association with an in-frame deletion in NUDT15 (chromosome 13, rs746071566) and TIM (5.8% [19/328] affected vs 0.2% [1/633] unaffected patients; OR, 38.2 [95% CI, 5.1 to 286.1], P = 1.3 × 10-8), which was replicated in a different cohort (2.7% [2/73] affected vs 0.2% [2/840] unaffected patients; OR, 11.8 [95% CI, 1.6 to 85.0], P = .03). Carriage of any of 3 coding NUDT15 variants was associated with an increased risk (OR, 27.3 [95% CI, 9.3 to 116.7], P = 1.1 × 10-7) of TIM, independent of TPMT genotype and thiopurine dose.Among patients of European ancestry with IBD, variants in NUDT15 were associated with increased risk of TIM. These findings suggest that NUDT15 genotyping may be considered prior to initiation of thiopurine therapy; however, further study including additional validation in independent cohorts is required." @default.
• W2917253389 created "2019-03-02" @default.
• W2917253389 creator A5002973845 @default.
• W2917253389 creator A5003568842 @default.
• W2917253389 creator A5004757455 @default.
• W2917253389 creator A5005948755 @default.
• W2917253389 creator A5013445087 @default.
• W2917253389 creator A5016465497 @default.
• W2917253389 creator A5017351131 @default.
• W2917253389 creator A5018859519 @default.
• W2917253389 creator A5019646038 @default.
• W2917253389 creator A5019960092 @default.
• W2917253389 creator A5020962383 @default.
• W2917253389 creator A5021559660 @default.
• W2917253389 creator A5024002886 @default.
• W2917253389 creator A5025804091 @default.
• W2917253389 creator A5030220173 @default.
• W2917253389 creator A5030564681 @default.
• W2917253389 creator A5031136418 @default.
• W2917253389 creator A5034149861 @default.
• W2917253389 creator A5035340036 @default.
• W2917253389 creator A5036281306 @default.
• W2917253389 creator A5036366637 @default.
• W2917253389 creator A5038738639 @default.
• W2917253389 creator A5040119863 @default.
• W2917253389 creator A5040981628 @default.
• W2917253389 creator A5041280886 @default.
• W2917253389 creator A5043997159 @default.
• W2917253389 creator A5045507391 @default.
• W2917253389 creator A5046490863 @default.
• W2917253389 creator A5047522708 @default.
• W2917253389 creator A5050440543 @default.
• W2917253389 creator A5051452881 @default.
• W2917253389 creator A5055734737 @default.
• W2917253389 creator A5056408708 @default.
• W2917253389 creator A5056977453 @default.
• W2917253389 creator A5060061551 @default.
• W2917253389 creator A5061087463 @default.
• W2917253389 creator A5066218040 @default.
• W2917253389 creator A5067725332 @default.
• W2917253389 creator A5068096434 @default.
• W2917253389 creator A5069067500 @default.
• W2917253389 creator A5069192514 @default.
• W2917253389 creator A5069238850 @default.
• W2917253389 creator A5073710029 @default.
• W2917253389 creator A5073977144 @default.
• W2917253389 creator A5079458166 @default.
• W2917253389 creator A5079706955 @default.
• W2917253389 creator A5083208590 @default.
• W2917253389 creator A5083701333 @default.
• W2917253389 creator A5087253187 @default.
• W2917253389 creator A5089763005 @default.
• W2917253389 date "2019-02-26" @default.
• W2917253389 modified "2023-10-01" @default.
• W2917253389 title "Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease" @default.
• W2917253389 cites W1528677968 @default.
• W2917253389 cites W1978270674 @default.
• W2917253389 cites W1995422727 @default.
• W2917253389 cites W2033151532 @default.
• W2917253389 cites W2035746880 @default.
• W2917253389 cites W2054802177 @default.
• W2917253389 cites W2064928200 @default.
• W2917253389 cites W2087936498 @default.
• W2917253389 cites W2089335658 @default.
• W2917253389 cites W2103441770 @default.
• W2917253389 cites W2104549677 @default.
• W2917253389 cites W2109000403 @default.
• W2917253389 cites W2147477044 @default.
• W2917253389 cites W2149633671 @default.
• W2917253389 cites W2172210794 @default.
• W2917253389 cites W2188248802 @default.
• W2917253389 cites W2254002107 @default.
• W2917253389 cites W2256016639 @default.
• W2917253389 cites W2275947820 @default.
• W2917253389 cites W2346052580 @default.
• W2917253389 cites W2384461891 @default.
• W2917253389 cites W2529241974 @default.
• W2917253389 cites W2607572977 @default.
• W2917253389 cites W2731117318 @default.
• W2917253389 cites W2791017116 @default.
• W2917253389 cites W2797152839 @default.
• W2917253389 cites W4230100678 @default.
• W2917253389 cites W4234215277 @default.
• W2917253389 cites W4235470812 @default.
• W2917253389 cites W4238765782 @default.
• W2917253389 cites W4245176030 @default.
• W2917253389 cites W4246395845 @default.
• W2917253389 cites W568926096 @default.
• W2917253389 doi "https://doi.org/10.1001/jama.2019.0709" @default.
• W2917253389 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6439872" @default.
• W2917253389 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30806694" @default.
• W2917253389 hasPublicationYear "2019" @default.
• W2917253389 type Work @default.
• W2917253389 sameAs 2917253389 @default.
• W2917253389 citedByCount "110" @default.
• W2917253389 countsByYear W29172533892019 @default.
• W2917253389 countsByYear W29172533892020 @default.
• W2917253389 countsByYear W29172533892021 @default.

• next